JTO Clinical and Research Reports (May 2022)

Creation of an Integrated Clinical Trial Database and Data Sharing for Conducting New Research by the Japan Lung Cancer Society

  • Yuichi Ozawa, MD, PhD,
  • Nobuyuki Yamamoto, MD, PhD,
  • Kouji Yamamoto, PhD,
  • Kentaro Ito, MD,
  • Hirotsugu Kenmotsu, MD, PhD,
  • Hidetoshi Hayashi, MD, PhD,
  • Takehito Shukuya, MD, PhD,
  • Daichi Fujimoto, MD, PhD,
  • Shunichi Sugawara, MD, PhD,
  • Seiji Niho, MD, PhD,
  • Yuichiro Ohe, MD, PhD,
  • Hiroaki Okamoto, MD, PhD,
  • Kazuhiko Nakagawa, MD, PhD,
  • Katsuyuki Kiura, MD, PhD,
  • Ichiro Yoshino, MD, PhD,
  • Akihiko Gemma, MD, PhD

Journal volume & issue
Vol. 3, no. 5
p. 100317

Abstract

Read online

Introduction: Although data accumulated in clinical trials have higher accuracy compared with real-world data and are irreplaceably valuable, most previous clinical trial data have been left unused. Methods: The Japan Lung Cancer Society (JLCS) asked six clinical trial groups that conducted randomized clinical trials on curative chemoradiation for locally advanced NSCLC to provide data. After obtaining consent from all six groups, data were collected from August 2019 to June 2021. Results: A total of eight trials, JCOG9812, JCOG0301, NJLCG0601, OLCSG0007, WJTOG0105, WJOG5008L, SPECTRA, and TORG1018, were included. More than 3000 data items were integrated into 408 items by adjusting their definitions and units. The total number of collected cases was 1288: median age (range), 66 (30–93) years; sex (male/female) 1064/224; pathological type (squamous cell carcinoma, adenocarcinoma, other NSCLC, and unknown) 517, 629, 138, and 4; and stage IIIA and B, 536 and 752. The median overall survival was 26.0 months, with 2-, 5-, and 10-year survival rates of 53.7%, 24.8%, and 15.2%, respectively, in all enrollments. The median progression-free survival was 9.6 months, with 2-, 5-, and 10-year progression-free survival rates of 23.6%, 14.0%, and 9.4%, respectively. Part of the information in the database has been made available on the JLCS web page, and the JLCS members were provided the right to propose research using the database. Conclusions: The integration and sharing of clinical trial data for research purposes was made real by the nonprofit, academic organization, the JLCS. This database will lead to innovative researches and contribute to the improvement of lung cancer treatment and future research.

Keywords